title: Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil.
abstract: BACKGROUND
  Renal dysfunction caused by treatment with the calcineurin inhibitors (CNI) is a major problem in the long-term course after liver transplantation.
  
  
  METHODS
  In 22 liver graft recipients with renal dysfunction and stable graft function between 3 weeks and 12 years after transplantation, CNI were substituted by MMF at a final dose of 1.5-3 g/day between October 1996 and October 1998.
  
  
  METHODS
  In a prospective non-randomized study, the development of renal function, the side effects of MMF medication, and the stability of liver function were analyzed for a mean follow-up of 15 months. Results. (1) MMF was withdrawn in four patients for major side effects between 1 and 7 months after study entry; eight patients had minor side effects. (2) Six months after study entry, renal function had improved in 17 of the 22 study patients; mean serum creatinine +/-SD (micromol/L) was 201+/-77 at entry and 153+/-65 after 3 months (P<0.001). (3) Improvement occurred in 11 of 15 patients with creatinine elevation > or =12 months and in 6 of 6 patients with creatinine elevation < or =6 months. (4) One patient developed transient liver dysfunction and a second required retransplantation for progressive cholestasis but without signs of rejection.
  
  
  CONCLUSIONS
  In patients who undergo liver transplantation, substitution of CNI by MMF leads to improvement of acute as well as chronic renal dysfunction in most cases. Side effects of MMF may be limiting in some patients, and the immunological consequences remain to be studied.
authors.affiliation: Klinik für Viszeral- und Transplantationschirurgie and Abteilung Gastroenterologie und Hepatologie, Medizinische Hochschule Hannover, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Barkmann
authors.forename: B
authors.initials: B
authors.lastname: Nashan
authors.forename: H H
authors.initials: HH
authors.lastname: Schmidt
authors.forename: K H
authors.initials: KH
authors.lastname: Böker
authors.forename: N
authors.initials: N
authors.lastname: Emmanouilidis
authors.forename: J
authors.initials: J
authors.lastname: Rosenau
authors.forename: M J
authors.initials: MJ
authors.lastname: Bahr
authors.forename: M W
authors.initials: MW
authors.lastname: Hoffmann
authors.forename: M P
authors.initials: MP
authors.lastname: Manns
authors.forename: J
authors.initials: J
authors.lastname: Klempnauer
authors.forename: H J
authors.initials: HJ
authors.lastname: Schlitt
mesh_terms: D000328:Adult; D000368:Aged; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000503:physiopathology; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid